Healthcare Equipment and Supplies
Company Overview of Cerevast Therapeutics, Inc.
Cerevast Therapeutics, Inc., a medical technology company, engages in the development of non-invasive treatments for acute ischemic stroke and other vascular disorders. It offers ClotBust-ER, an operator independent device, which helps in administering ultrasound energy for sonothrombolysis therapy. Cerevast Therapeutics, Inc. was formerly known as WA32609 Inc. The company was founded in 2009 and is headquartered in Redmond, Washington.
12277 134th Court NE
Redmond, WA 98052
Founded in 2009
Key Executives for Cerevast Therapeutics, Inc.
Vice President of Operations
Vice President of Quality
Compensation as of Fiscal Year 2014.
Cerevast Therapeutics, Inc. Key Developments
Cerevast Therapeutics, Inc. Initiates Phase 3 Clotbust ER Clinical Study for the Treatment of Acute Ischemic Stroke
Aug 1 13
Cerevast Therapeutics, Inc. announced that it has initiated patient enrollment in its Phase 3 clinical trial evaluating the use of the company's proprietary Clotbust ER ultrasonic headframe for the treatment of acute ischemic stroke. This worldwide study intends to enroll up to 800 ischemic stroke patients in a randomized, double-blinded clinical trial designed to evaluate the efficacy and safety of the Clotbust ER ultrasound device when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase). The Clotbust ER Phase 3 clinical study is being conducted at over 60 leading stroke centers in 14 countries worldwide. The trial will enroll ischemic stroke patients with baseline National Institute of Health Stroke Scale (NIHSS) scores of 10 or greater. Patients will be randomized (400 per arm) to either Clotbust ER ultrasound in combination with IV tPA therapy or standard IV tPA therapy alone. The primary endpoint of the study is 90-day functional outcome as measured by the percentage of patients that achieve a modified Rankin (mRS) score of 0-1 at 90 days post-treatment. The study will also evaluate complete vessel recanalization as a secondary endpoint in a subset of patients that undergo pre and post-treatment MRI or CT angiography. Two interim analyses are scheduled to be performed by the study's Data Safety Monitoring Board (DSMB) upon completion of one-third and two-thirds of enrollment.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 13, 2013
Most Searched Private Companies
Sponsored Financial Commentaries